Global Core Biopsy Needles Market Size By Type (14G-18G, <14G), By Application (Lung Cancer, Liver Cancer), By Region, And Segment Forecasts, 2023 to 2032

lobal Core Biopsy Needles Market Report Description

The Global Core Biopsy Needles Market was valued at USD 580 million in 2023 and is projected to reach USD 965 million by 2031, expanding at a CAGR of 6.9% during the forecast period (2023–2031).

The growth of this market is driven by the rising incidence of cancer and tumor-related diseases, increasing demand for minimally invasive diagnostic procedures, and advancements in biopsy needle design and imaging guidance technologies. Core biopsy needles play a vital role in obtaining tissue samples for histopathological examination, aiding in the accurate diagnosis of malignancies and other chronic conditions.

The shift towards outpatient-based and image-guided biopsy procedures, coupled with the integration of advanced ultrasound and MRI technologies, is further accelerating the adoption of core biopsy needles worldwide.

Drivers

Rising Cancer Prevalence

Increasing global cancer burden is the primary driver for core biopsy needles. Breast, lung, and prostate cancers account for the majority of biopsy procedures.

Growing Preference for Minimally Invasive Diagnostics

Patients and healthcare providers prefer minimally invasive techniques that reduce recovery time and hospital stays, boosting demand for core biopsy needles.

Technological Advancements in Biopsy Devices

Innovations like vacuum-assisted biopsy systems, real-time imaging integration, and ergonomic needle designs are enhancing diagnostic accuracy and efficiency.

Restraints

Risk of Complications

Despite being minimally invasive, biopsies can lead to bleeding, infection, or tissue trauma, which can deter some patients and clinicians.

High Cost of Advanced Biopsy Systems

Image-guided and vacuum-assisted core biopsy devices involve higher costs, limiting their adoption in resource-constrained settings.

Opportunities

Rising Healthcare Investments in Emerging Markets

Expansion of cancer diagnostic facilities in Asia-Pacific and Latin America presents significant growth potential.

Integration with AI-based Imaging and Robotics

AI-assisted biopsy targeting and robotic needle placement can enhance precision, creating new opportunities for advanced product launches.

Growing Demand for Outpatient Biopsy Procedures

The shift from inpatient to outpatient care supports the adoption of cost-effective, portable biopsy devices.

Market by System Type Insights

Automatic Core Biopsy Needles held the largest market share in 2023, driven by ease of use and higher procedural success rates.

Semi-Automatic Core Biopsy Needles are expected to witness the fastest growth due to their affordability and versatility in different tissue types.

Market by End-use Insights

Hospitals & Cancer Diagnostic Centers dominate the market, accounting for over 55% of global revenue in 2023 due to the rising number of cancer patients.

Ambulatory Surgical Centers (ASCs) are anticipated to grow at the highest CAGR as they offer faster, outpatient biopsy services with reduced cost burden.

Market by Regional Insights

North America led the market in 2023 with the largest share, supported by advanced healthcare infrastructure, high cancer screening rates, and strong presence of key players.

Asia-Pacific is projected to grow at the highest rate, fueled by improving healthcare access, increasing cancer awareness, and investments in diagnostic imaging technologies.

Europe maintains a significant market share with well-established cancer screening programs and reimbursement policies.

Competitive Scenario

Key players in the Global Core Biopsy Needles Market include:

BD (Becton, Dickinson and Company)

Hologic, Inc.

Cook Medical

Argon Medical Devices, Inc.

Devicor Medical Products (part of Leica Biosystems)

Cardinal Health

INRAD Inc.

Stryker Corporation

These companies are focusing on strategic partnerships, product innovation, and mergers & acquisitions to expand their portfolio of biopsy devices.

Recent Developments:

2024: BD launched a next-generation vacuum-assisted biopsy needle compatible with AI-enabled imaging platforms.

2023: Hologic expanded its breast biopsy device portfolio with enhanced ultrasound-guided biopsy systems.

2023: Cook Medical introduced a cost-effective semi-automatic biopsy needle for emerging markets.

Scope of Work – Global Core Biopsy Needles Market

Key Market Developments

July 2024: BD partnered with an AI imaging start-up to develop intelligent biopsy guidance systems.

March 2024: Argon Medical Devices received FDA approval for a novel semi-automatic biopsy needle optimized for lung tissue sampling.

January 2023: Hologic completed the acquisition of a European biopsy device manufacturer to strengthen its regional footprint.

FAQs

What is the current market size of the Global Core Biopsy Needles Market?

The market was valued at USD 580 million in 2023.

What is the major growth driver of the Global Core Biopsy Needles Market?

The major growth driver is the increasing prevalence of cancer and the rising demand for minimally invasive diagnostic procedures.

Which is the largest region during the forecast period in the Global Core Biopsy Needles Market?

North America remains the largest region due to advanced cancer care infrastructure and high screening rates.

Which segment accounted for the largest market share in the Global Core Biopsy Needles Market?

Automatic Core Biopsy Needles accounted for the largest share in 2023.

Who are the key market players in the Global Core Biopsy Needles Market?

Key players include BD, Hologic, Cook Medical, Argon Medical Devices, and Stryker Corporation.

Would you like me to also create a visually formatted one-page summary of this report for presentation or quick reference?